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Abstract Using a low-energy diet as a tool, it has been pos-
sible to elucidate the sequence of pathophysiological changes
that lead to the onset of type 2 diabetes. Negative energy
balance in type 2 diabetes causes a profound fall in liver fat
content resulting in normalisation of hepatic insulin sensitivity
within 7 days. As the period of negative energy balance ex-
tends and liver fat levels fall to low normal, the rate of export
of triacylglycerol from the liver falls. Consequent to this, the
raised pancreas fat content falls and in early type 2 diabetes,
normal first-phase insulin secretion becomes re-established
with normal plasma glucose control. This research, driven
by the predictions of the 2008 twin cycle hypothesis, has led
to a paradigm shift in understanding. Studying the reversed
sequence of pathophysiological changes, the linked abnormal-
ities in liver and pancreas have been revealed. Early type 2
diabetes is a potentially reversible condition. Surprisingly, it
was observed that the diet devised as an experimental tool was
actually liked by research participants. It was associated nei-
ther with hunger nor tiredness in most people, but with rapidly
increased wellbeing. A defined period of weight loss followed
by carefully planned weight maintenance—the ‘One, Two’
approach—has since been applied in clinical practice.
Motivated individuals can reverse their type 2 diabetes and
remain normoglycaemic over years. A large study is under-
way to evaluate the applicability of this general approach to
routine primary care practice as a long-term management
strategy.
Keywords Aetiology . Beta cell function . Liver fat .
Low-energy diet . Management . Pancreas fat .
Pathophysiology . Type 2 diabetes .Weight loss .Weight
maintenance
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Introduction
A new concept of aetiology of type 2 diabetes resulted from
several new research observations in 2006 [1]. Over the past
decade the predictions of this twin cycle hypothesis have been
tested using as a dynamic tool a low-energy diet [2, 3]. A new,
simplified view of the physiological basis of type 2 diabetes has
emerged, and this points to a novel approach to management.
The nutritional intervention designed to evaluate the physiolog-
ical basis of the twin cycle hypothesis was observed to be
surprisingly well accepted by research participants, and thera-
peutic use has followed. Weight loss averaging 15% of body
weight is reproducibly obtained with potential reversal of type
2 diabetes to a sustained non-diabetic state. Although the effect
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of weight loss in bringing about resolution of type 2 diabetes is
not new, the easily explained pathophysiology enhances en-
gagement. Additionally, the routinely reproducible method of
bringing about and sustaining 15% weight loss permits clinical
application. This review summarises the new information,
bringing together metabolic knowledge of disease mechanisms
with details of proven nutritional approaches.
The new understanding of type 2 diabetes
The new hypothesis predicted that there weremetabolic vicious
cycles operating in liver and pancreas, and that these should be
able to be reversed. The primary driver of the metabolic prob-
lem was identified as positive energy balance, and reversing
this was predicted to restore normal blood glucose control
(Fig. 1) [1]. Each step shown in Fig. 1 has subsequently been
tested and confirmed.
In individuals with a short duration of type 2 diabetes, an
average of 15% weight loss allowed fasting plasma glucose to
return to normal within 7 days [2]. The rapid return to normal
was associated with a 30% decrease in liver fat content and
normalisation of liver insulin sensitivity. The COUNTERacting
Pancreatic inhibitiOn of INsulin secretion by Triglyceride
(Counterpoint) study also demonstrated that over the 8 week
study period the level of fat in the pancreas gradually decreased
and in step with this, first-phase insulin response returned to
within the normal range [2]. In contrast, there was no change
in muscle insulin resistance.
If the observed changes did represent normalisation of the
underlying mechanisms of type 2 diabetes, rather than merely
the effect of underfeeding, the beneficial changes should per-
sist after return to normal eating. This was tested in the
COUNTERacting BetA cell failure by Long term Action to
Normalize Calorie intakE (Counterbalance) study. During a
6 month period of weight stability, levels of fat in the liver
and pancreas remained constant, with normal function of these
organs in those individuals returned to non-diabetic metabolic
control (Fig. 2) [9].
Importantly, after the 15% weight loss in Counterbalance,
half of the participants still had a BMI > 30 kg/m2, but this had
no impact upon their ability to avoid subsequent intra-organ fat
re-accumulation. Each individual had dropped below a person-
al threshold permitting safe storage of fat in the subcutaneous
Positive energy balance
Pre-existing muscle 
insulin resistance ++
Liver fat
Resistance to insulin 
suppression of 
glucose production
Basal insulin 
secretion
Liver 
cycle
Pancreas 
cycle
VLDL-triacylglycerol Islet triacylglycerol
Beta cell 
de-differentiation
Postprandial 
glucose
Plasma glucose
Insulin response to 
ingested glucose
Subcutaneous fat 
depot
X
Fig. 1 The 2008 twin cycle hypothesis. During chronic intake of more
energy than is expended each day, any carbohydrate in excess of require-
ment must undergo conversion to fat in the liver to permit storage of the
metabolic energy as fat [4]. As this process is sensitive to endogenous
insulin, individuals with a degree of insulin resistance (and hence higher
plasma insulin levels) will tend to accumulate liver fat more readily than
others. If the subcutaneous adipose tissue stores have reached capacity,
the newly synthesised fat will accumulate in the liver together with excess
dietary fat. There it inhibits insulin suppression of glucose production by
the liver, and a vicious cycle of hyperinsulinaemia and increased glucose
production becomes established. Too much fat in the liver leads to in-
creased export of fat in the form of VLDL-triacylglycerol [5] (shown in
lighter red to indicate this is secondary to loss of insulin suppression of
liver glucose production). When subcutaneous fat storage capacity is
exhausted (i.e. exceeds the personal fat threshold), this will increase fat
delivery to all tissues, and the pancreatic islets take up fat avidly [6].
Postprandial hyperglycaemia causes increased and prolonged insulin se-
cretion with further stimulation of de novo lipogenesis. This second vi-
cious cycle thus further increases de novo lipogenesis, and fat delivery to
the pancreas. Over many years, the excess pancreas fat brings about loss
of specialised function and de-differentiation of the beta cell [7].
Eventually, the inhibitory effects of fatty acids and glucose on the islets
reach a trigger level leading to a relatively sudden onset of clinical dia-
betes. The twin cycle hypothesis predicted that both vicious cycles could
be reversed by inducing negative energy balance. Figure adapted from [1]
and [8]
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compartment, and this was equally so whether their BMI
dropped from 40 to 36 kg/m2 or from 28 to 24 kg/m2. This
illustrates the important concept of the personal fat threshold
[10]. The ability to store fat safely in adipose tissue varies
considerably between individuals with otherwise normal
metabolism [11, 12], and once that capacity has been exceeded
the body has to use other storage sites, including liver and
pancreas. Individuals can exceed their personal fat threshold
at BMIs well within the normal range, as illustrated by the
finding that the type 2 diabetes prevalence for women with a
BMI of < 22 kg/m2 is 4.3-fold that for women with a BMI of
23–24 kg/m2 [13]. That is a remarkable increase in relative risk
for an increase in BMI that small within the ‘normal’ range. In
the United Kingdom Prospective Diabetes Study [14], 36% had
a BMI < 25 kg/m2. The distribution is right-shifted from that of
the UK population of that time, when 64% had a BMI
< 25 kg/m2 [15]. As the risk of type 2 diabetes rises steeply at
higher BMIs, and higher BMIs are now more prevalent, the
association between obesity and type 2 diabetes is much more
evident today. It is important to recognise BMI as a descriptor
for populations (for which the measure was originally
developed), rather than a measure to interpret precisely at the
level of the individual.
The observation that type 2 diabetes appeared to be a state of
excess fat in the pancreas causing the pathognomonic defect in
beta cell function, raises the question of how the fat could be
interfering with beta cell function. A series of studies has dem-
onstrated that excess saturated fat produces endoplasmic retic-
ulum stress, and that this is associated with de-differentiation of
the beta cell [16–19]. It appears to enter a survival mode in
which its specialised functions are shut down. Removal of the
fat allows re-expression of the insulin gene and resumption of
acute glucose-mediated insulin secretion [7].
Understanding what is happening in the pancreas is the key
to type 2 diabetes, as the condition never occurs without a
major decrease in acute insulin secretion [20, 21]. The volume
of the pancreas in type 2 diabetes is only a half to two-thirds
that of people with normal glucose tolerance [22, 23]. Also,
the pancreas in type 2 diabetes has a markedly irregular
border. As a consequence, when selecting a volume of tissue
by imaging to be within the pancreas it is more difficult to
include only pancreas parenchyma and not the visceral fat that
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Fig. 2 The Counterbalance study. Thirty people with type 2 diabetes of
up to 23 years duration lost approximately 15 kg in weight then main-
tained steady weight for 6 months. Those achieving non-diabetic fasting
plasma glucose levels were classified as responders and those whose
levels remained in the diabetic range, as non-responders. In (b-d) the
three columns for each group represent (from left to right) baseline on
usual drug therapy; after weight loss, on an isoenergetic diet; and after a
further 6 months of weight stability. (a) The change in HbA1c in re-
sponders (circles) and non-responders (triangles). (b) There was a similar
and sustained decrease in liver fat content in both groups despite ongoing
overweight or obesity. (c) In the responders, pancreas fat decreased to low
levels, but in the non-responders only fell to levels equivalent to baseline
responder levels. (d) At baseline, the first-phase insulin response was
higher in responders and increased to normal levels, whereas the grossly
deficient baseline level in non-responders hardly changed. Although non-
responders normalise both liver fat content and liver insulin sensitivity,
plasma glucose remains elevated in the absence of normalised beta cell
function and low fasting plasma insulin levels [9]. *p < 0.05; **p < 0.01
vs baseline. To convert HbA1c values from % to mmol/mol, subtract 2.15
and multiply by 10.929. Triglyceride is elsewhere referred to as
triacylglycerol. Copyright: ADA [9]. Copyright and all rights reserved.
Material from this publication has been used with the permission of ADA
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fills in the irregular margin. Additionally, fat within the
pancreas comprises both intracellular fat, which is metaboli-
cally active, and fat in scattered isolated adipocytes, and
imaging methods cannot distinguish between these. Hence,
the observed range of fat content is wide in normal and
diabetic individuals. This explains the failure of cross-
sectional studies to distinguish a difference in total pancreas
fat between groups of people with or without type 2 diabetes
[24–26]. Induced differences in the metabolically active frac-
tion are evident only in longitudinal studies using precise
magnetic resonance technology [2, 3, 9]. After acute weight
loss, pancreas fat decreases only in people with type 2 diabetes
[3]. Because identification of a tissue volume entirely within
the pancreas is difficult, an ‘MR-opsy’ method has been
developed to biopsy uniformly sized, small volumes within
the pancreas to increase precision and to permit comparison of
data between different institutions [27]. The higher the
pancreas fat, the lower the pancreas volume, and the nature
of this relationship requires further work, perhaps in animal
models. The abnormalities of low pancreas volume and
irregularity of pancreas border in type 2 diabetes are striking,
and further studies are urgently required to understand the
relationship between these changes and with both fat content
of the organ and aetiology of the condition.
Type 2 diabetes is commonly regarded as being hetero-
geneous, with possible differing aetiologies in different
groups requiring specific approaches to therapy [28].
Individuals vary markedly with respect to any physiological
variable, and both genetic and environmental heterogeneity
is clear [29]. However, it must be considered that the ob-
served heterogeneity resides in the individuals, not in the
basic mechanisms of disease. A parallel could be drawn with
observations on the effect of changing an indisputably single
mechanism. For example, lisinopril exerts very different ef-
fects on blood pressure in different individuals [30].
Observation of the heterogeneity of response to antihyper-
tensive therapy (due to ethnic, genetic and environmental
factors affecting each individual) may be interpreted by an
observer blinded to the nature of the therapy to suggest that
several different drugs are being used. In reality, a single
drug is being applied to individuals who respond in a het-
erogeneous manner. In the same way, the single cause of
ectopic fat affecting beta cell function, revealed by the stud-
ies discussed above, could be misinterpreted as different
specific causes. These considerations apply only to type 2
diabetes itself—a very common condition. There are some
clear-cut rare conditions such as monogenic, slow-onset type
1 and pancreatic diabetes that must be considered when
making a diagnosis, and there may be other rare conditions
that are as yet unrecognised. However, type 2 diabetes itself
is a disease so simple that prevalence increases dramatically
when a population has ready access to cheap food and
decreases when food is scarce [31, 32]. When the Pima
Indians were living as subsistence farmers, a comprehensive
health survey reported only one case of diabetes, and Joslin
famously observed no diabetes at that time [33, 34]. Yet
subsequent overnutrition revealed susceptibility to type 2
diabetes in around 40% of the population [35]. Added to
this is the steadily increasing beta cell defect as disease
duration increases in any one individual, indicating that du-
ration must be taken into account in comparing groups. The
lack of precise knowledge of duration of disease in most
people adds to apparent heterogeneity. Hence, it is postulat-
ed that anyone who develops true type 2 diabetes has accu-
mulated more fat in the pancreas than they individually can
tolerate. The cause of this common disease is not heteroge-
neous, unlike the individuals.
The hypothesis-driven sequence of studies revealing the
pathogenesis of type 2 diabetes by observing changes dur-
ing the return to normal glucose metabolism is illustrated
in Fig. 3.
Testing the twin cycle hypothesis by inducing 15%
weight loss
Conventional dietetic approaches to achieving weight loss are
not notably successful. The prolonged nature of most inter-
ventions is a drawback, and the two major adverse factors
associated with this approach are hunger and daily decisions
about what and howmuch to eat. These potentially modifiable
factors were accounted for in the design of the Counterpoint
and Counterbalance studies with a short, time-limited weight
loss phase and a subsequent weight maintenance phase—a
‘One, Two’ approach.
To induce weight loss, a liquid formula diet provided in
individual meal sachets was used (2.51 MJ [600 kcal]/day;
three sachets). To minimise constipation, up to 240 g/day of
non-starchy vegetables were allowed. The total energy intake
was thus around 2.93 MJ (700 kcal)/day. A relatively high
sugar content was necessary for palatability, but this did not
prevent normalisation of fasting plasma glucose within 7 days
despite withdrawal of oral hypoglycaemic agents [2].
Unexpectedly, the dietary approach adopted to allow the hy-
pothesis to be tested was actually liked by the participants.
Counterbalance demonstrated that the individuals who did
not return to non-diabetic blood glucose control typically had a
longer disease duration, but notably already had severely im-
paired beta cell function at baseline [9]. Weight loss produced
normalisation of liver fat content with normalisation of hepatic
insulin sensitivity in all, but this alone was insufficient to nor-
malise glucose control. The apparent heterogeneity of response
lay in the duration-dependent progression to complete beta cell
de-differentiation, whereby those individuals with beta cells still
at the reversible stages could achieve complete re-differentiation
and resumption of beta cell specialist function [7].
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All participants reported almost complete lack of hunger
within 1–2 days of commencing the diet. This is striking dur-
ing achievement of ~ 15 kg weight loss. Notable wellbeing
was reported [37]. Several participants wished to continue the
low-energy liquid diet after the 8 week period of the study to
meet their own weight target. A recent systematic review ex-
poses the misconception that rapid weight gain inevitably fol-
lows rapid weight loss [38]. If weight loss by any regimen is
not followed up by a supportive programme it is unlikely to be
sustained. In Counterbalance, participants were seen at
monthly intervals for the 6 month follow-up period and
weight remained stable. Importantly, they were advised in
advance to expect to be eating only two-thirds of their usual
intake of food. The concept that weight loss is more difficult to
achieve in people with type 2 diabetes is incorrect [38].
Following media interest in the Counterpoint results, a
large number of emails and letters were received from
people with diabetes, and full how-to-do-it information
was placed on the Magnetic Resonance Centre website
[39]. Analysis of the initial email responses to the infor-
mation showed that half had used a liquid diet replace-
ment, and half had used small portions of ordinary foods
[40]. Weight loss was approximately 15 kg in both
groups, illustrating the practical possibility of achieving
this degree of weight loss by any energy-restricted ap-
proach that is sustainable. There was clearly an important
matter of individual preference.
Nature of the ongoing support required
after reversal of diabetes
The liquid low-energy diet is prescriptive, rendering it reas-
suringly straightforward to follow. In contrast, the prospect of
returning to normal eating after the liquid diet, with inherent
decisions about what and how much to eat, is often a time of
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Fig. 3 Testing the twin cycle
hypothesis. The Counterpoint
study established that negative
energy balance brought about
normalisation of liver fat and
insulin sensitivity to suppression
of liver glucose production within
7 days, and normalisation of
pancreas fat with normalisation of
first-phase insulin response over
8 weeks [2]. The Counterbalance
study demonstrated that if weight
was kept steady after rapid weight
loss then the normalisation of
liver and pancreas fat content and
function was durable during
normal, isoenergetic eating [9]. It
also showed that reversibility
became much less likely after
10 years’ duration of type 2
diabetes. In vitro studies on
insulin-producing cells
demonstrate that excess fat
provision reversibly decreases
glucose-stimulated insulin
production and that this is due to
de-differentiation of beta cells [8,
16, 18]. Studies of acute weight
loss produced by bariatric surgery
observe a decrease in pancreas fat
in people who used to have
diabetes and not in non-diabetic
individuals [3]. The practicality of
achieving long-term reversal of
type 2 diabetes in primary care is
currently being evaluated in a
head-to-head comparison with
conventional management [36]
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great anxiety. RCTevidence confirms that a gradual transition
to the weight maintenance diet following weight loss with a
low- or very-low-energy diet over a period of weeks is asso-
ciated with improved weight maintenance at 12 months [41,
42]. A gradual, stepwise change from the low-energy liquid
diet to normal foodstuffs was employed in the subsequent
studies. During this phase of Counterbalance, weekly face-
to-face review was undertaken, with directive advice on what
and how much to eat, consideration being given to individual
dietary preferences and calculated energy requirements. The
energy prescription for weight stabilisation was estimated
from achieved body weight using predictive equations [43].
Additional telephone support was also available. Monthly re-
view and weekly self-weighing was then undertaken [44],
resulting in weight stability over 6 months. One critical ingre-
dient for success was observed to be family support. If the
spouse or partner was not supportive, then the chance of
long-term success was low. Notably, in both Counterpoint
and Counterbalance spouses/partners reported losing weight
as well. Changing the obesogenic microenvironment of the
home is critical.
While some individuals can successfully maintain a new
lower body weight under their own direction [40], most are
likely to require ongoing support to limit weight regain over
time [45]. The support that may be required during weight loss
maintenance is summarised in Fig. 4.
Nature of ongoing diet
An individual who has achieved remission of type 2 diabetes
through weight loss remains inherently predisposed to recur-
rence if there is a return to chronic energy excess. It is therefore
of utmost importance to maintain the body weight at a level
below the personal fat threshold. However, long-term mainte-
nance of lost weight is recognised as the most challenging aspect
of obesity treatment [46]. With appropriate support, significant
weight loss can be maintained over the longer term [47].
Sowhich dietary strategy is most appropriate? A low-fat diet
(< 30% total energy from fat) has long been the mainstay of
dietary advice. This is traceable to the association of high fat
intake with cardiovascular death reported in the seven countries
study [48]. Epidemiological associations from cross-sectional
studies have been shown repeatedly not to represent cause and
effect [49], but the belief is ingrained in practice and reflected in
current guidelines for type 2 diabetes. However, it is now well
established that it is adherence to any strategy rather than a
particular macronutrient composition which is likely to result
in long-term weight maintenance. Over recent years nutrition
guidelines have moved away from prescriptive macronutrient
content towards a more person-centred philosophy, acknowl-
edging that there is no ‘one best diet’ for diabetes [50]. Three
evidenced approaches (low carbohydrate, Mediterranean and
intermittent energy restriction) are discussed in the following
section as potential options for amaintenance diet following the
initial rapid weight loss period.
Formany Europeans, decreasing or omitting the carbohydrate
portion of the main meal, with or without change in other meals,
is a simple change, easily achievable in the context of family
eating. Low-carbohydrate diets (less than 120 g per day of total
carbohydrate) and very-low-carbohydrate diets (20–50 g total
carbohydrate per day) for diabetes management continue to ex-
cite vehement debate [49, 51]. A carbohydrate-restricted diet
implies an increase in the ratio of fat to carbohydrate, conflicting
Weekly self-weighing 
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Fig. 4 Components of support to provide long-term weight stability. The
major components of support for the individual are indicated. As eating is
a social activity, the wider context must be taken into account.
Maintenance of support from family/a partner is critical, and understand-
ing from friends and work colleagues is also key, along with coping
strategies where such support is absent. All of these points require explo-
ration at ongoing follow-up visits. Not illustrated in the diagram is input
of outside agencies as required and the crucial potential for the whole
obesogenic environment to be influenced by policy makers
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with long-held beliefs about the risks of higher-fat diets. There is
insufficient evidence to recommend an ideal proportion of total
energy from carbohydrate in diabetes management [52]. For
equivalent weight loss, different compositions of diet do not
affect liver fat content nor any other aspect of fat distribution
[53]. Despite incorporation into evidence-based nutrition guide-
lines in 2011 [50], UK clinical practice relating to carbohydrate
restriction has not kept pace with the evidence base [54]. Low-
carbohydrate diets have been reported to be superior to low-fat
diets for short to medium term use in type 2 diabetes, with
comparable longer-term (> 12 months) outcomes [55].
The Mediterranean diet is based on a combination of food-
stuffs high in monounsaturated fats (primarily olive oil), le-
gumes and vegetables, and with restricted red meat, processed
foods and refined carbohydrates. Such diets consistently give
benefit in terms of weight control and cardiovascular health
[56–58]. A decrease in diabetes incidence independent of
weight has also been observed [59]. Given the current evi-
dence, the Mediterranean diet could be recommended as an
option for a weight maintenance diet regardless of diabetes
remission status. A combined Mediterranean and
carbohydrate-restricted diet may be particularly beneficial
for those for whom weight loss has not resulted in diabetes
remission, almost halving the need for diabetes drugs over
4 years following diagnosis of type 2 diabetes [60].
Novel time-limited approaches to eating (alternate day or
intermittent fasting, time-restricted eating and meal timing
during the day) provide an alternative to daily energy restric-
tion. Intermittent energy restriction achieved by a variety of
methods is as effective as daily energy restriction in achieving
weight loss and maintenance for up to 12 months [61]. Weight
loss outcomes were better in studies that applied an energy
prescription on the non-fasting (‘feed’) days in order to ensure
an overall weekly deficit. In some studies mean weight losses
were similar between groups but the proportion of participants
losing a clinically significant amount of weight (≥ 5%) was
higher with intermittent energy reduction (60–65% at
12 weeks) compared with the daily energy restriction group
(37%) [62]. One day of energy restriction per week main-
tained the improvements in weight and insulin sensitivity
(achieved using a 5:2 approach) over 6 months of follow-up
in overweight or obese women. The first published results
using the 5:2 approach in a population with type 2 diabetes
demonstrate comparable reductions in weight and HbA1c be-
tween daily and intermittent energy-restricted groups with no
adverse effects on exercise levels or appetite [63, 64].
Evidence relating to the use of this approach for longer-term
weight maintenance is lacking and warrants further study.
Studies reporting an association of omission of breakfast
with increased weight usually have a clear commercial bias
[65]. Prospective study reveals no disbenefit of omitting
breakfast in terms of eating more later in the day and demon-
strates the potential major energy advantage [66]. For some
individuals omission of breakfast may usefully contribute to
long-term weight control if they do not like breakfast and can
readily extend the overnight fast to lunchtime [67].
As different dietary approaches are likely to suit the needs
and preferences of different individuals (especially those who
have had little success with conventional low-fat diets), a deci-
sion aid such as that developed to facilitate informed choices
about diabetes medications may be a useful tool. Long-term
weight control will be most effectively achieved by finding
an approach to eating that an individual, and their family, can
sustain. The composition (restricted carbohydrate/restricted fat)
is far less important than the overall quantity of food, and there
are varying, equally valid ways of achieving this goal.
Physical activity
There is clear-cut evidence for encouraging sustainable, daily
physical activity during the long-term weight maintenance
phase, alongside energy control [68]. This is of great impor-
tance. However, little attention has been paid to the compen-
satory eating phenomenon, which is a major hazard of the
weight loss phase itself [69–71]. If overweight or obese indi-
viduals embark upon an exercise regimen, there tends to be an
increase in weight due to an increase in energy intake, partly
conscious and partly subconscious. This varies between indi-
viduals [70], but extra exercise can be avoided with no dis-
benefit to substantial weight loss. The energy expenditure
during exercise that is tolerated by most overweight, older
people is modest and easily cancelled out by a snack.
During the weight loss phase of both Counterpoint and
Counterbalance, participants were asked to continue usual ac-
tivities but to avoid any increase in physical activity. This
appeared to contribute to the achievement of the target
~ 15% weight loss in 8 weeks. In contrast, the more widely
used approach of advising an increase in exercise from the
beginning of a longer-term period of a diet withmodest energy
restriction may contribute to falling short of the weight loss
target [72]. A randomised study testing the effect of avoiding
additional prescribed exercise during the weight loss phase of
any energy-restricted diet may be helpful in clarifying the
effectiveness of this approach.
Previous studies of weight loss as management
for type 2 diabetes
Observation of the beneficial effect of weight loss on blood
glucose control is not new. Ayurvedic scriptures from
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2000 years ago recognised fat and thin forms of diabetes and
recommended fasting and exercise [73]. Bouchardat described
the resolution of glycosuria in diabetes during the famine
caused by the 1870 siege of Paris [74]. Allen’s low-energy
diet also permitted prolonged survival of individuals with
what is now recognised as type 1 diabetes [75]. Energy restric-
tion brought about by bariatric surgery has long been known
to return blood glucose control to normal in some people [76].
A 6 day very-low-energy diet supervised in hospital was
shown to improve fasting plasma glucose from 18.6 to
11.2 mmol/l, but in common with all such studies did not
consider the effect of long duration of diabetes [77]. Two
studies are notable in using a low-energy diet with follow-up
over 1 year [78] and 5 years [79] to demonstrate the beneficial
effect on glucose control. In the latter study, one out of 15
remained normoglycaemic off all medications, giving a very
favourable ‘number needed to treat’ for the complete reversal
of diabetes.
The only older study to have used a very-low-energy diet as
a tool to evaluate mechanisms of disease was published in
1986 [80]. In-patient supervision of a 1.38–2.51 MJ/day
(330–600 kcal/day) diet for up to 40 days was followed by
60–380 days of outpatient follow-up. This study specifically
avoided additional exercise in the weight loss phase, and is
one of the few in which participants achieved weight loss of
around 15%. This decrease caused a fall in fasting plasma
glucose from 15.4 to 6.8 mmol/l, which correlated with a fall
in hepatic glucose output. However, the study group of eight
included people with a long duration of diabetes, and no change
was observed in average insulin response to oral glucose.
Lifelong reversal of type 2 diabetes?
Information from observational studies on large groups of
people with type 2 diabetes suggest an inexorable wors-
ening of blood glucose control with a need for increasing
numbers of tablets and, eventually, insulin [81, 82]. The
associated demonstration of a steady decline in beta cell
function [83] has given rise to the widespread belief that
this is inevitable. However, these observational studies
were carried out only in the situation of maintained or
increasing body weight [84].
The demonstration that the non-diabetic control of glucose
metabolism is fully maintained over 6 months is useful in
confirming the mechanistic basis of long-term remission of
type 2 diabetes [9]. In those who had achieved a post-
weight-loss fasting plasma glucose of < 7 mmol/l, liver and
pancreas fat content fell to normal levels. First-phase insulin
response became and remained normal. There was no accu-
mulation of fat in either pancreas or liver, even though mean
BMI was 30 kg/m2 [9]. These data are important in clarifying
the physiological basis of continuing reversal of type 2 diabe-
tes, separate from the well-recognised human problem of
avoiding weight regain in the face of unchanged environmen-
tal pressures. Longer-term data are required from formal
studies, but non-diabetic metabolic control can be maintained
over several years, providing that weight regain is avoided
[72, 79, 85].
The Diabetes Remission Clinical Trial (DiRECT) is a
large randomised trial that will determine the effectiveness
of rapid weight loss followed by supportive follow-up in
primary care, head-to-head with conventional management
[36]. It will report 12 month outcomes at the end of 2017.
The intervention consists of 8 h of training for the practice
nurse (or practice dietitian if available), with continuing spe-
cialist dietitian support. All oral glucose-lowering agents are
withdrawn. The dietary and behavioural approach known as
CounterWeight has been trialled for obesity management in
primary care with 1 year follow-up demonstrating mainte-
nance of ≥ 15 kg weight loss in 30% [47]. DiRECT will
address the question of selection bias and degree of self-
motivation that follows from the smaller, pathophysiological
studies. It will also provide further evidence of the basic
mechanisms of disease. Rapid recruitment to DiRECT re-
flects the extreme dislike of type 2 diabetes by many people.
This is generally underestimated by professionals and, given
the previous lack of means to restore normal metabolism,
has led to a situation of learned helplessness. The outcomes
of DiRECT may indicate an important way forward.
A single cause of common type 2 diabetes can 
be postulated
Type 2 diabetes appears to be caused by 
reversible de-differentiation of beta cells follow-
ing excess fat exposure in those susceptible 
Heterogeneity lies in the individuals, not the 
basic mechanism of disease 
Evidence-based means of achieving 15% 
weight loss in clinical practice are described
Low-carbohydrate, Mediterranean and intermit-
tent-fasting diets have an evidence base to 
justify use to minimise weight regain
A supportive approach to these dietary strat-
egies in routine care is required to maximise 
favourable long-term outcomes
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